Waldenstrom Macroglobulinemia
"Waldenstrom Macroglobulinemia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.
| Descriptor ID |
D008258
|
| MeSH Number(s) |
C04.557.595.925 C14.907.454.960 C15.378.147.780.925 C15.378.463.515.960 C15.604.515.925 C20.683.780.925
|
| Concept/Terms |
Waldenstrom Macroglobulinemia- Waldenstrom Macroglobulinemia
- Macroglobulinemia, Waldenstrom
- Lymphoma, Lymphoplasmacytoid
- Lymphomas, Lymphoplasmacytoid
- Lymphoplasmacytoid Lymphoma
- Lymphoplasmacytoid Lymphomas
- Macroglobulinemia
- Waldenstrom's Macroglobulinemia
- Macroglobulinemia, Waldenstrom's
- Waldenstroms Macroglobulinemia
- Waldenstrom's Macroglobulinaemia
- Macroglobulinaemia, Waldenstrom's
- Waldenstrom Macroglobulinaemia
- Waldenstroms Macroglobulinaemia
- Lymphoma, Lymphocytic, Plasmacytoid
- Primary Macroglobulinemia
- Macroglobulinemia, Primary
Familial Waldenstrom's Macroglobulinaemia- Familial Waldenstrom's Macroglobulinaemia
- Familial Waldenstrom Macroglobulinaemia
- Familial Waldenstroms Macroglobulinaemia
- Macroglobulinaemia, Familial Waldenstrom's
- Waldenstrom's Macroglobulinaemia, Familial
|
Below are MeSH descriptors whose meaning is more general than "Waldenstrom Macroglobulinemia".
Below are MeSH descriptors whose meaning is more specific than "Waldenstrom Macroglobulinemia".
This graph shows the total number of publications written about "Waldenstrom Macroglobulinemia" by people in this website by year, and whether "Waldenstrom Macroglobulinemia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2009 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2014 | 6 | 0 | 6 |
| 2015 | 9 | 0 | 9 |
| 2016 | 19 | 1 | 20 |
| 2017 | 9 | 1 | 10 |
| 2018 | 24 | 0 | 24 |
| 2019 | 8 | 0 | 8 |
| 2020 | 14 | 0 | 14 |
| 2021 | 14 | 0 | 14 |
| 2022 | 11 | 0 | 11 |
| 2023 | 8 | 0 | 8 |
| 2024 | 9 | 1 | 10 |
| 2025 | 11 | 0 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Waldenstrom Macroglobulinemia" by people in Profiles.
-
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenstr?m macroglobulinemia. Blood Adv. 2025 Oct 14; 9(19):4842-4847.
-
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenstr?m macroglobulinemia: a pooled analysis. Blood Adv. 2025 Sep 23; 9(18):4705-4715.
-
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenstr?m macroglobulinemia. Blood Adv. 2025 Sep 23; 9(18):4568-4579.
-
Simultaneous Presentation of Cutaneous Waldenstr?m Macroglobulinemia and Acalabrutinib-Related Toxicity. Am J Dermatopathol. 2025 Oct 01; 47(10):786-789.
-
Diagnosis and Management of Waldenstrom's Macroglobulinemia. Hematol Oncol. 2025 Jun; 43 Suppl 2:e70071.
-
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenstr?m macroglobulinaemia. Br J Haematol. 2025 Jun; 206(6):1604-1614.
-
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors. Semin Hematol. 2025 Apr; 62(2):113-119.
-
Current and emerging treatment perspectives for adults with Waldenstr?m macroglobulinemia. Expert Rev Anticancer Ther. 2025 May; 25(5):485-497.
-
Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia. Am J Hematol. 2025 Jun; 100(6):980-986.
-
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenstr?m macroglobulinemia. Blood Adv. 2025 Feb 25; 9(4):722-728.